Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic ...

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

As India grapples with an escalating diabetes crisis, with 101 million1 diagnosed and 136 million with pre-diabetes, the ...

Diabetic retinopathy is a common complication of diabetes, which manifests as a potentially severe eye disease that can lead ...

A new study published in the Nature Scientific Reports showed that compared to kidney recipients who got preemptive transplants, individuals who experienced dialysis prior to transplantation are ...

Exonate has announced plans to initiate a phase 2b clinical trial of its lead candidate EXN407, a topical SRPK1 inhibitor, ...

Danegaptide, a potential oral therapy for nonproliferative diabetic retinopathy, is advancing to a phase 2 trial after ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...